Tobacco smoke-induced lung fibrosis and emphysema

Annual Review of Physiology

Volumn 76, Issue , 2014, Pages 493-513

  Morse, Danielle ^a   Rosas, Ivan O ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

Autophagy; COPD; Inflammasome; IPF; Senescence; TGF

Indexed keywords

AGING; ANIMALS; AUTOPHAGY; CARRIER PROTEINS; CHRONIC DISEASE; DNA DAMAGE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PULMONARY EMPHYSEMA; PULMONARY FIBROSIS; SMOKE; SMOKING; TELOMERE; TOBACCO SMOKE POLLUTION;

EID: 84894149898     PISSN: 00664278     EISSN: 15451585     Source Type: Book Series    
DOI: 10.1146/annurev-physiol-021113-170411     Document Type: Review

References (161)

1. Stockley RA, Mannino D, Barnes PJ. 2009. Burden and pathogenesis of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 6:524-266
2. Baumgartner KB, Samet JM, Stidley CA, Colby TV, Waldron JA. 1997. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am. J. Respir. Crit. CareMed. 155:242-488
3. Selman M, King TE, Pardo A. 2001. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann. Intern. Med. 134:136-511
4. MejiaM, Carrillo G, Rojas-Serrano J, Estrada A, SuarezT, et al. 2009. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 136:10-155
5. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, et al. 2011. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N. Engl. J. Med. 364:897-9066
6. Dornhorst AC. 1955. Respiratory insufficiency. Lancet 268:1185-877
7. Rahman I, Skwarska E, HenryM,Davis M, O'ConnorCM, et al. 1999. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 27:60-688
8. MacNee W. 2000. Oxidants/antioxidants and COPD. Chest 117:S303-177
9. Calabrese F, Giacometti C, Beghe B, Rea F, Loy M, et al. 2005. Marked alveolar apoptosis/proliferation imbalance in end-stage emphysema. Respir Res. 6:144
10. Hodge S, Hodge G, Holmes M, Reynolds PN. 2005. Increased airway epithelial and T-cell apoptosis in COPD remains despite smoking cessation. Eur. Respir. J. 25:447-544
11. AoshibaK,Nagai A. 2009. Senescence hypothesis for the pathogeneticmechanism of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 6:596-6011
12. Cronkhite JT, Xing C, Raghu G, Chin KM, Torres F, et al. 2008. Telomere shortening in familial and sporadic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 178:729-377
13. Ito K, Barnes PJ. 2009. COPD as a disease of accelerated lung aging. Chest 135:173-800
14. Wu L, Chau J, Young RP, Pokorny V,Mills GD, et al. 2004. Transforming growth factor-β1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax 59:126-299
15. Celedon JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, et al. 2004. The transforming growth factor-β1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum. Mol. Genet. 13:1649-566
16. Morris DG, Huang X, Kaminski N,Wang Y, Shapiro SD, et al. 2003. Loss of integrin v β6-mediated TGF-βactivation causes Mmp12-dependent emphysema. Nature 422:169-733
17. Wang X, Inoue S, Gu J, Miyoshi E, Noda K, et al. 2005. Dysregulation of TGF-β1 receptor activation leads to abnormal lung development and emphysema-like phenotype in core fucose-deficient mice. Proc. Natl. Acad. Sci. USA 102:15791-966
18. Colarossi C, Chen Y, Obata H, Jurukovski V, Fontana L, et al. 2005. Lung alveolar septation defects in Ltbp-3-null mice. Am. J. Pathol. 167:419-288
19. Bonniaud P, Kolb M, Galt T, Robertson J, Robbins C, et al. 2004. Smad3 null mice develop airspace enlargement and are resistant to TGF-mediated pulmonary fibrosis. J. Immunol. 173:2099-1088
20. Lee CG, Cho S, Homer RJ, Elias JA. 2006. Genetic control of transforming growth factor-1-induced emphysema and fibrosis in the murine lung. Proc. Am. Thorac. Soc. 3:476-777
21. Gately I. 2004. Tobacco: A Cultural History of How an Exotic Plant Seduced Civilization. New York: Grove. 1st ed..
22. Benowitz NL. 2008. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin. Pharmacol. Ther. 83:531-411
23. Smith CJ, Livingston SD, Doolittle DJ. 1997. An international literature survey of "IARC Group I carcinogens" reported in mainstream cigarette smoke. Food Chem. Toxicol. 35:1107-300
24. EzzatiM, Lopez AD. 2003. Measuring the accumulated hazards of smoking: global and regional estimates for 2000. Tob. Control 12:79-855
25. US Dep. Health Hum. Serv. 2012. Preventing tobacco use among youth and young adults: A report of the Surgeon General. Washington, DC: US Dep. Health Hum. Serv..
26. Mannino DM. 2002. COPD: epidemiology, prevalence, morbidity and mortality, and disease heterogeneity. Chest 121:S121-266
27. Flaherty KR, Hunninghake GG. 2005. Smoking: an injury with many lung manifestations. Am. J. Resp. Crit. Care Med. 172:1070-711
28. Baumgartner K, Samet J, Stidley C, Colby T, Waldron J. 1997. Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. Am. J. Resp. Crit. Care Med. 155:242-488
29. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, et al. 2011. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am. J. Resp. Crit. Care Med. 183:788-8244
30. Antoniou KM,Hansell DM, Rubens MB,MartenK,Desai SR, et al. 2008. Idiopathic pulmonary fibrosis: outcome in relation to smoking status. Am. J. Respir. Crit. CareMed. 177:190-944
31. Rosas IO, Ren P, Avila NA, Chow CK, Franks TJ, et al. 2007. Early interstitial lung disease in familial pulmonary fibrosis. Am. J. Respir. Crit. CareMed. 176:698-7055
32. Remy-Jardin M, Remy J, Boulenguez C, Sobaszek A, Edme JL, Furon D. 1993. Morphologic effects of cigarette smoking on airways and pulmonary parenchyma in healthy adult volunteers: CT evaluation and correlation with pulmonary function tests. Radiology 186:107-155
33. Niewoehner DE, Kleinerman J, Rice DB. 1974. Pathologic changes in the peripheral airways of young cigarette smokers. N. Engl. J. Med. 291:755-588
34. Katzenstein AL, Mukhopadhyay S, Zanardi C, Dexter E. 2010. Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens. Hum. Pathol. 41:316-255
35. Steele MP, Speer MC, Loyd JE, Brown KK, Herron A, et al. 2005. Clinical and pathologic features of familial interstitial pneumonia. Am. J. Respir. Crit. CareMed. 172:1146-522
36. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, et al. 2011. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N. Engl. J. Med. 364:897-9066
37. Washko GR, Lynch DA, Matsuoka S, Ross JC, Umeoka S, et al. 2010. Identification of early interstitial lung disease in smokers from the COPDGene Study. Acad. Radiol. 17:48-533
38. Talikka M, Sierro N, Ivanov NV, Chaudhary N, Peck MJ, et al. 2012. Genomic impact of cigarette smoke, with application to three smoking-related diseases. Crit. Rev. Toxicol. 42:877-899
39. Yang IV. 2012. Epigenomics of idiopathic pulmonary fibrosis. Epigenomics 4:195-2033
40. Papageorgis P, Lambert AW,Ozturk S,Gao F, PanH, et al. 2010. Smad signaling is required tomaintain epigenetic silencing during breast cancer progression. Cancer Res. 70:968-788
41. Rennard SI. 2004. Looking at the patient-approaching the problem of COPD. N. Engl. J.Med. 350:965-966
42. Raherison C, Girodet PO. 2009. Epidemiology of COPD. Eur. Respir. Rev. 18:213-211
43. Salvi SS, Barnes PJ. 2009. Chronic obstructive pulmonary disease in non-smokers. Lancet 374:733-433
44. Taraseviciene-Stewart L, Voelkel NF. 2008. Molecular pathogenesis of emphysema. J. Clin. Investig. 118:394-4022
45. Kuhn C, Yu SY,Chraplyvy M, Linder HE, Senior RM. 1976. The induction of emphysema with elastase. II. Changes in connective tissue. Lab. Investig. 34:372-800
46. Hautamaki RD, Kobayashi DK, Senior RM, Shapiro SD. 1997. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 277:2002-44
47. Tuder RM, Petrache I. 2012. Pathogenesis of chronic obstructive pulmonary disease. J. Clin. Investig. 122:2749-555
48. Rangasamy T, Cho CY, Thimmulappa RK, Zhen L, Srisuma SS, et al. 2004. Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice. J. Clin. Investig. 114:1248-599
49. RaghuG,Weycker D, Edelsberg J, Bradford WZ, Oster G. 2006. Incidence and prevalence of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. CareMed. 174:810-166
50. Raghu G, Freudenberger TD, Yang S, Curtis JR, Spada C, et al. 2006. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur. Respir. J. 27:136-422
51. Enomoto T, Usuki J, Azuma A, Nakagawa T, Kudoh S. 2003. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest 123:2007-111
52. Taskar VS, Coultas DB. 2006. Is idiopathic pulmonary fibrosis an environmental disease? Proc. Am. Thorac. Soc. 3:293-988
53. Pinheiro GA, Antao VC, Wood JM, Wassell JT. 2008. Occupational risks for idiopathic pulmonary fibrosis mortality in the United States. Int. J. Occup. Environ. Health 14:117-233
54. Chapman HA. 2011. Epithelial-mesenchymal interactions in pulmonary fibrosis. Annu. Rev. Physiol. 73:413-355
55. Scotton CJ, Krupiczojc MA, Konigshoff M, Howell DC, McAnulty RJ, et al. 2009. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J. Clin. Investig. 119:2550-633
56. Hecker L, Vittal R, Jones T, Jagirdar R, Luckhardt TR, et al. 2009. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat. Med. 15:1077-811
57. Lawson WE, Cheng DS, Degryse AL, Tanjore H, Polosukhin VV, et al. 2011. Endoplasmic reticulum stress enhances fibrotic remodeling in the lungs. Proc. Natl. Acad. Sci. USA 108:10562-677
58. Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, et al. 2009. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am. J. Hum. Genet. 84:52-599
59. Nogee LM, Wert SE, Proffit SA, Hull WM, Whitsett JA. 2000. Allelic heterogeneity in hereditary surfactant protein B (SP-B) deficiency. Am. J. Respir. Crit. Care Med. 161:973-811
60. Nogee LM, Dunbar AE 3rd, Wert SE, Askin F, Hamvas A, Whitsett JA. 2001. A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N. Engl. J. Med. 344:573-799
61. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, et al. 2007. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356:1317-266
62. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, et al. 2007. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc. Natl. Acad. Sci. USA 104:7552-577
63. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, et al. 2011. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 364:1503-122
64. Steele MP, Schwartz DA. 2013. Molecular mechanisms in progressive idiopathic pulmonary fibrosis. Annu. Rev. Med. 64:265-766
65. Alder JK, Guo N, Kembou F, Parry EM, Anderson CJ, et al. 2011. Telomere length is a determinant of emphysema susceptibility. Am. J. Respir. Crit. Care Med. 184:904-122
66. Aoshiba K, Zhou F, Tsuji T, Nagai A. 2012. DNA damage as a molecular link in the pathogenesis of COPD in smokers. Eur. Respir. J. 39:1368-766
67. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, et al. 2007. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356:1317-266
68. Borie R, Crestani B, Bichat H. 2009. Prevalence of telomere shortening in familial and sporadic pulmonary fibrosis is increased in men. Am. J. Respir. Crit. CareMed. 179:10733
69. MacNee W. 2009. Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem. Soc. Trans. 37:819-233
70. Stewart SA, Weinberg RA. 2002. Senescence: Does it all happen at the ends? Oncogene 21:627-300
71. Greider CW. 1996. Telomere length regulation. Annu. Rev. Biochem. 65:337-655
72. Harley CB, Vaziri H, Counter CM, Allsopp RC. 1992. The telomere hypothesis of cellular aging. Exp. Gerontol. 27:375-822
73. Tsakiri KD, Cronkhite JT, Kuan PJ, Xing C, Raghu G, et al. 2007. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc. Natl. Acad. Sci. USA 104:7552-577
74. Alder JK, Chen JJ, Lancaster L, Danoff S, Su SC, et al. 2008. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc. Natl. Acad. Sci. USA 105:13051-566
75. LiuT,Chung MJ,Ullenbruch M, Yu H, JinH, et al. 2007. Telomerase activity is required for bleomycininduced pulmonary fibrosis in mice. J. Clin. Investig. 117:3800-99
76. Savale L, Chaouat A, Bastuji-Garin S, Marcos E, Boyer L, et al. 2009. Shortened telomeres in circulating leukocytes of patientswith chronic obstructive pulmonary disease.Am. J. Respir. Crit.CareMed. 179:566-711
77. Fumagalli M, Rossiello F, Clerici M, Barozzi S, Cittaro D, et al. 2012. Telomeric DNA damage is irreparable and causes persistent DNA-damage-response activation. Nat. Cell Biol. 14:355-655
78. Xue J,Duncan SR. 2009. Are telomere lengths of leukocytes from patients with pulmonary fibrosis really genetically determined? Am. J. Respir. Crit. CareMed. 179:852; author reply 8533
79. Boulton SJ, Jackson SP. 1998. Components of the Ku-dependent non-homologous end-joining pathway are involved in telomeric length maintenance and telomeric silencing. EMBO J. 17:1819-288
80. Schulz VP, Zakian VA, Ogburn CE, McKay J, Jarzebowicz AA, et al. 1996. Accelerated loss of telomeric repeatsmay not explain accelerated replicative decline ofWerner syndrome cells. Hum. Genet. 97:750-544
81. Shiloh Y, Tabor E, Becker Y. 1985. In vitro phenotype of ataxia-telangiectasia (AT) fibroblast strains: clues to the nature of the "AT DNA lesion" and the molecular defect in AT. Kroc Found. Ser. 19:111-211
82. Chen QM, Prowse KR, Tu VC, Purdom S, Linskens MH. 2001. Uncoupling the senescent phenotype from telomere shortening in hydrogen peroxide-treated fibroblasts. Exp. Cell Res. 265:294-3033
83. Suzuki K, Mori I, Nakayama Y, Miyakoda M, Kodama S, Watanabe M. 2001. Radiation-induced senescence-like growth arrest requires TP53 function but not telomere shortening. Radiat. Res. 155:248-533
84. von Zglinicki T, Burkle A, Kirkwood TB. 2001. Stress, DNA damage and ageing -an integrative approach. Exp. Gerontol. 36:1049-622
85. Walter CA, Grabowski DT, Street KA, Conrad CC, Richardson A. 1997. Analysis and modulation of DNA repair in aging. Mech. Ageing Dev. 98:203-222
86. DeMarini DM. 2004. Genotoxicity of tobacco smoke and tobacco smoke condensate: a review. Mutat. Res. 567:447-744
87. Shi Y, Cao J, Gao J, Zheng L, Goodwin A, et al. 2012. Retinoic acid-related orphan receptor-is induced in the setting of DNA damage and promotes pulmonary emphysema. Am. J. Respir. Crit. Care Med. 186:412-199
88. NakashimaN,KuwanoK,Maeyama T, Hagimoto N, YoshimiM, et al. 2005. The p53-Mdm2 association in epithelial cells in idiopathic pulmonary fibrosis and non-specific interstitial pneumonia. J. Clin. Pathol. 58:583-899
89. Morissette MC, Vachon-Beaudoin G, Parent J, Chakir J,Milot J. 2008. Increased p53 level, Bax/Bcl-xL ratio, and TRAIL receptor expression in human emphysema. Am. J. Respir. Crit. CareMed. 178:240-477
90. Wilson DO, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, et al. 2008. Association of radiographic emphysema and airflow obstruction with lung cancer. Am. J. Respir. Crit. Care Med. 178:738-444
91. Schwartz AG, Cote ML, Wenzlaff AS, Land S, Amos CI. 2009. Chronic obstructive lung diseases and risk of non-small cell lung cancer in women. J. Thorac. Oncol. 4:291-999
92. Park J,KimDS, ShimTS, LimCM, KohY, et al. 2001. Lung cancer in patientswith idiopathic pulmonary fibrosis. Eur. Respir. J. 17:1216-199
93. Hersh CP, Pillai SG, Zhu G, Lomas DA, Bakke P, et al. 2010. Multi-study fine mapping of chromosome 2q identifies XRCC5 as a COPD susceptibility gene. Am. J. Respir. Crit. CareMed. 182:605-133
94. Wang Y, Ghosh G, Hendrickson EA. 2009. Ku86 represses lethal telomere deletion events in human somatic cells. Proc. Natl. Acad. Sci. USA 106:12430-355
95. Chen Z, Trotman LC, Shaffer D, LinHK, Dotan ZA, et al. 2005. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436:725-300
96. Caramori G, Adcock IM, Casolari P, Ito K, Jazrawi E, et al. 2011. Unbalanced oxidant-induced DNA damage and repair in COPD: a link towards lung cancer. Thorax 66:521-277
97. Hoeijmakers JH. 2009. DNA damage, aging, and cancer. N. Engl. J. Med. 361:1475-855
98. Davis T, Kipling D. 2006. Werner Syndrome as an example of inflamm-aging: possible therapeutic opportunities for a progeroid syndrome? Rejuvenation Res. 9:402-77
99. Patel BD, Loo WJ, Tasker AD, Screaton NJ, Burrows NP, et al. 2006. Smoking related COPD and facial wrinkling: Is there a common susceptibility? Thorax 61:568-711
100. OharaT,Hirai T,Muro S, Haruna A, Terada K, et al. 2008. Relationship between pulmonary emphysema and osteoporosis assessed by CT in patients with COPD. Chest 134:1244-499
101. SchmidtMI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, et al. 1999. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet 353:1649-522
102. Sin DD, Man SF. 2003. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107:1514-199
103. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. 2009. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur. Respir. J. 34:380-866
104. Selman M, Pardo A, Kaminski N. 2008. Idiopathic pulmonary fibrosis: aberrant recapitulation of developmental programs? PLoS Med. 5:e622
105. Konigshoff M, Kramer M, Balsara N, Wilhelm J, Amarie OV, et al. 2009. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J. Clin. Investig. 119:772-877
106. CignaN, FarrokhiMoshaiE, Brayer S,Marchal-Somme J,Wemeau-StervinouL, et al. 2012. The hedgehog systemmachinery controls transforming growth factor-dependent myofibroblastic differentiation in humans: involvement in idiopathic pulmonary fibrosis. Am. J. Pathol. 181:2126-377
107. Lam AP, Gottardi CJ, Tuder R. 2011. Regenerative pathways and emphysema: a new paradigm? Am. J. Respir. Crit. Care Med. 183:688-900
108. Kasahara Y, Tuder RM, Taraseviciene-Stewart L, Le Cras TD, Abman S, et al. 2000. Inhibition of VEGF receptors causes lung cell apoptosis and emphysema. J. Clin. Investig. 106:1311-199
109. LeeCG, Cho SJ, Kang MJ,Chapoval SP,Lee PJ, et al. 2004. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor 1-induced pulmonary fibrosis. J. Exp.Med. 200:377-899
110. Xu B, Chen H, Xu W, ZhangW, Buckley S, et al. 2012. Molecular mechanisms ofMMP9overexpression and its role in emphysema pathogenesis of Smad3-deficient mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 303:L89-966
111. Klionsky DJ. 2007. Autophagy: from phenomenology to molecular understanding in less than a decade. Nat. Rev. Mol. Cell Biol. 8:931-377
112. Blommaart EF, Luiken JJ, Blommaart PJ, van Woerkom GM, Meijer AJ. 1995. Phosphorylation of ribosomal protein S6 is inhibitory for autophagy in isolated rat hepatocytes. J. Biol. Chem. 270:2320-266
113. Matsuura A, Tsukada M, Wada Y, Ohsumi Y. 1997. Apg1p, a novel protein kinase required for the autophagic process in Saccharomyces cerevisiae. Gene 192:245-500
114. Hosokawa N, Hara T, Kaizuka T, Kishi C, Takamura A, et al. 2009. Nutrient-dependent mTORC1 association with the ULK1-Atg13-FIP200 complex required for autophagy. Mol. Biol. Cell 20:1981-911
115. Di Bartolomeo S, Corazzari M, Nazio F, Oliverio S, Lisi G, et al. 2010. The dynamic interaction of AMBRA1 with the dynein motor complex regulates mammalian autophagy. J. Cell Biol. 191:155-688
116. Wirawan E, Vanden Berghe T, Lippens S, Agostinis P, Vandenabeele P. 2012. Autophagy: for better or for worse. Cell Res. 22:43-611
117. Ravikumar B, Sarkar S, Davies JE, FutterM, Garcia-Arencibia M, et al. 2010. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol. Rev. 90:1383-4355
118. Levine B. 2005. Eating oneself and uninvited guests: autophagy-related pathways in cellular defense. Cell 120:159-622
119. Ryter SW, Nakahira K, Haspel JA, Choi AMK. 2012. Autophagy in pulmonary diseases. Annu. Rev. Physiol. 74:377-4011
120. KunduM, Thompson CB. 2008. Autophagy: basic principles and relevance to disease. Annu. Rev. Pathol. 3:427-555
121. Levine B, Abrams J. 2008. p53: the Janus of autophagy? Nat. Cell Biol. 10:637-399
122. Chen ZH, Kim HP, Sciurba FC, Lee SJ, Feghali-Bostwick C, et al. 2008. Egr-1 regulates autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. PLoS ONE 3:e33166
123. Chen ZH, Lam HC, Jin Y, Kim HP, Cao J, et al. 2010. Autophagy protein microtubule-associated protein 1 light chain-3B (LC3B) activates extrinsic apoptosis during cigarette smoke-induced emphysema. Proc. Natl. Acad. Sci. USA 107:18880-855
124. Monick MM, Powers LS, Walters K, Lovan N, Zhang M, et al. 2010. Identification of an autophagy defect in smokers' alveolar macrophages. J. Immunol. 185:5425-355
125. Brugarolas J, Lei K,Hurley RL, Manning BD, Reiling JH, et al. 2004. Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1/TSC2 tumor suppressor complex. Genes Dev. 18:2893-9044
126. Yoshida T, Mett I, Bhunia AK, Bowman J, Perez M, et al. 2010. Rtp801, a suppressor of mTOR signaling, is an essential mediator of cigarette smoke-induced pulmonary injury and emphysema. Nat. Med. 16:767-733
127. Patel AS, Lin L, Geyer A, Haspel JA, An CH, et al. 2012. Autophagy in idiopathic pulmonary fibrosis. PLoS ONE 7:e413944
128. Korfei M, Ruppert C, Mahavadi P, Henneke I, Markart P, et al. 2008. Epithelial endoplasmic reticulum stress and apoptosis in sporadic idiopathic pulmonary fibrosis. Am. J. Respir. Crit. CareMed. 178:838-466
129. Kliment CR, Oury TD. 2010. Oxidative stress, extracellular matrix targets, and idiopathic pulmonary fibrosis. Free Radic. Biol. Med. 49:707-177
130. Yorimitsu T, Nair U, Yang Z, Klionsky DJ. 2006. Endoplasmic reticulum stress triggers autophagy. J. Biol. Chem. 281:30299-3044
131. Kiffin R, Bandyopadhyay U, Cuervo AM. 2006. Oxidative stress and autophagy. Antioxid. Redox Signal. 8:152-622
132. Korfhagen TR, Le Cras TD, Davidson CR, Schmidt SM, Ikegami M, et al. 2009. Rapamycin prevents transforming growth factor-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 41:562-722
133. Ryter SW, Lee SJ, Choi AMK. 2010. Autophagy in cigarette smoke-induced chronic obstructive pulmonary disease. Expert Rev. Respir. Med. 4:573-844
134. Mariathasan S, Monack DM. 2007. Inflammasome adaptors and sensors: intracellular regulators of infection and inflammation. Nat. Rev. Immunol. 7:31-400
135. LommatzschM, Cicko S,Muller T, Lucattelli M, Bratke K, et al. 2010. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am. J. Respir. Crit. CareMed. 181:928-344
136. Mortaz E, Folkerts G, Nijkamp FP, Henricks PA. 2010. ATP and the pathogenesis of COPD. Eur. J. Pharmacol. 638:1-44
137. Cicko S, Lucattelli M, MullerT, LommatzschM,DeCunto G, et al. 2010. Purinergic receptor inhibition prevents the development of smoke-induced lung injury and emphysema. J. Immunol. 185:688-977
138. Churg A, Zhou S,Wang X,Wang R,Wright JL. 2009. The role of interleukin-1in murine cigarette smoke-induced emphysema and small airway remodeling. Am. J. Respir. Cell Mol. Biol. 40:482-900
139. Birrell MA, Eltom S. 2011. The role of the NLRP3 inflammasome in the pathogenesis of airway disease. Pharmacol. Ther. 130:364-700
140. Reilkoff RA, Peng H, Murray LA, Peng X, Russell T, et al. 2013. Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-1-induced pulmonary fibrosis. Am. J. Respir. Crit. CareMed. 187:180-888
141. Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, et al. 2013. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am. J. Respir. Crit. Care Med. 187:768-755
142. DostertC,Petrilli V, Van BruggenR, SteeleC,MossmanBT, Tschopp J. 2008. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320:674-777
143. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. 2001. Transient expression of IL-1induces acute lung injury and chronic repair leading to pulmonary fibrosis. J. Clin. Investig. 107:1529-366
144. Gasse P, Riteau N, Charron S,Girre S, Fick L, et al. 2009. Uric acid is a danger signal activatingNALP3 inflammasome in lung injury inflammation and fibrosis. Am. J. Respir. Crit. Care Med. 179:903-133
145. Houghton AM. 2013. Mechanistic links between COPD and lung cancer. Nat. Rev. Cancer 13:233-455
146. Hubbard R, Venn A, Lewis S, Britton J. 2000. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study. Am. J. Respir. Crit. CareMed. 161:5-88
147. Washko GR, Hunninghake GM, Fernandez IE, Nishino M, Okajima Y, et al. 2011. Lung volumes and emphysema in smokers with interstitial lung abnormalities. N. Engl. J. Med. 364:897-9066
148. Todd JL, Goldstein DB, Ge D, Christie J, Palmer SM. 2011. The state of genome-wide association studies in pulmonary disease: a new perspective. Am. J. Respir. Crit. Care Med. 184:873-800
149. Silverman EK, Vestbo J, Agusti A, Anderson W, Bakke PS, et al. 2011. Opportunities and challenges in the genetics of COPD 2010: an International COPD Genetics Conference report. COPD 8:121-355
150. Pillai SG, Ge D, Zhu G, Kong X, Shianna KV, et al. 2009. A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci. PLoS Genet. 5:e10004211
151. DeMeo DL, Mariani T, Bhattacharya S, Srisuma S, Lange C, et al. 2009. Integration of genomic and genetic approaches implicates IREB2 as a COPD susceptibility gene. Am. J. Hum. Genet. 85:493-5022
152. Wilk JB, Chen T-h, Gottlieb DJ, Walter RE, Nagle MW, et al. 2009. A genome-wide association study of pulmonary function measures in the Framingham Heart Study. PLoS Genet. 5:e10004299
153. Zhou X, Qiu W, Sathirapongsasuti JF, Cho MH, Mancini JD, et al. 2013. Gene expression analysis uncovers novel hedgehog interacting protein (HHIP) effects in human bronchial epithelial cells. Genomics 101:263-722
154. ChoMH, Boutaoui N, Klanderman BJ, Sylvia JS, Ziniti JP, et al. 2010. Variants inFAM13Aare associated with chronic obstructive pulmonary disease. Nat. Genet. 42:200-22
155. HancockDB, EijgelsheimM,Wilk JB,Gharib SA, Loehr LR, et al. 2010. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. Nat. Genet. 42:45-522
156. Richens TR, Linderman DJ, Horstmann SA, Lambert C, Xiao YQ, et al. 2009. Cigarette smoke impairs clearance of apoptotic cells through oxidant-dependent activation of RhoA. Am. J. Respir. Crit. Care Med. 179:1011-211
157. Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, et al. 2011. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 364:1503-122
158. Fingerlin TE,Murphy E, Zhang W, Peljto AL, Brown KK, et al. 2013. Genome-wide association study identifies multiple susceptibility loci for pulmonary fibrosis. Nat. Genet. 45:613-200
159. Peljto AL, Zhang Y, Fingerlin TE, Ma SF, Garcia JG, et al. 2013. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA 309:2232-399
160. Hunninghake GM, Hatabu H, Okajima Y, Gao W, Dupuis J, et al. 2013. MUC5B promoter polymorphism and interstitial lung abnormalities. N. Engl. J. Med. 368:2192-2000
161. Armanios MY, Chen JJ, Cogan JD, Alder JK, Ingersoll RG, et al. 2007. Telomerase mutations in families with idiopathic pulmonary fibrosis. N. Engl. J. Med. 356:1317-266